Human epidermal growth factor receptor 2 trang 1 tải miễn phí từ TAILIEUCHUNG

"Human epidermal growth factor receptor 2" trang 1 - tải miễn phí từ Tailieuchung

Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A systematic review

Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A systematic review

9 37 1

Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival

Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival

9 34 1

The SystHERs registry: An observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

The SystHERs registry: An observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

11 35 1

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

11 54 1

Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions

Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions

14 66 1

Atypical ubiquitin ligase RNF31: The nuclear factor modulator in breast cancer progression

Atypical ubiquitin ligase RNF31: The nuclear factor modulator in breast cancer progression

8 69 1

UPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R

UPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R

12 26 1

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study

7 43 3

Poor prognosis of single hormone receptorpositive breast cancer: Similar outcome as triple-negative breast cancer

Poor prognosis of single hormone receptorpositive breast cancer: Similar outcome as triple-negative breast cancer

9 50 1

Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration

Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration

15 29 1

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: Retrospective analysis from Leeds Cancer Centre

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: Retrospective analysis from Leeds Cancer Centre

12 67 0

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

9 80 0

Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study

Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study

13 56 1

Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer

Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer

17 34 1

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

8 36 1

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

13 39 1

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

7 41 1

Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

13 65 0

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

9 82 0

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

6 43 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.